94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1508226
Anlotinib for the Treatment of Recurrent and Refractory Hemangioblastomas: A Case Report and Review of Literature
Provisionally accepted
Qing Tian 1 Chaofeng Zhou 1 Shifan Zhou 1 Sai Wang 1 Baorong Feng 1 Keke Zhang 1
Yu Zhang 1 Jieqiong Gao 1 Xiaoyan Mu 2*
Zhizhong Guo 1*- 1 Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China
- 2 Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China
Hemangioblastomas (HBs) are rare, highly vascular tumors that present significant treatment challenges, especially in cases of multiple recurrences. Here we present our experience treating one patient with recurrent and refractory HBs, aiming to provide preliminary data on the use of anlotinib in treating this disease. An 18-year-old woman with recurrent and refractory HBs, treated at the Henan Provincial Hospital of Traditional Chinese Medicine, achieved disease remission through oral anlotinib treatment after recurrence. After being diagnosed with HBs, the patient underwent multiple surgical treatments with some efficacy. After recurrence, additional surgery and radiotherapy were not feasible due to the presence of multiple tumor sites. Oral anlotinib (10mg, qd, q3w) resulted in disease remission and significantly improved the patient's quality of life. Anlotinib may be employed in the management of recurrent and refractory HBs.
Keywords: Anlotinib, Hemangioblastoma, anti-angiogenesis, literature review, case report
Received: 01 Nov 2024; Accepted: 21 Feb 2025.
Copyright: © 2025 Tian, Zhou, Zhou, Wang, Feng, Zhang, Zhang, Gao, Mu and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaoyan Mu, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China
Zhizhong Guo, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.